Milestone director granted 77,000 stock options
Milestone Pharmaceuticals Inc. director Andrew Saik received a grant of stock options as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Milestone Pharmaceuticals Inc. director Andrew Saik received a grant of stock options as part of his compensation. The award covers 77,000 options to buy common stock at an exercise price of $1.22 per share.
The options vest in twelve equal monthly installments starting on July 10, 2026, and will in any case be fully vested by the date of the company’s next annual stockholder meeting, as long as Saik continues to provide service through each vesting date. Following this grant, he holds 77,000 options directly.
Insider Trade Summary
Grant/Award: 77,000 shares
Grant/Award
1 txn
Insider
Saik Andrew
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 77,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 77,000 contracts (Direct)
Footnotes (1)
- F1. This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Key Figures
Options granted: 77,000 options
Exercise price: $1.22 per share
Expiration date: June 10, 2036
+3 more
6 metrics
Options granted
77,000 options
Grant to director Andrew Saik
Exercise price
$1.22 per share
Stock option strike price
Expiration date
June 10, 2036
Option term end
Underlying shares
77,000 shares
Common stock underlying options
Post-grant option holdings
77,000 options
Total options held directly after grant
Vesting schedule
12 equal monthly installments
Beginning July 10, 2026
Key Terms
Stock Option (right to buy), derivative security, exercise price, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
derivative security financial
"transaction_type: derivative"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise price financial
"conversion_or_exercise_price: 1.2200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"This option will vest in twelve (12) equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-06-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Milestone Pharmaceuticals (MIST) director Andrew Saik report in this Form 4?
Andrew Saik reported receiving a grant of stock options for 77,000 shares of Milestone Pharmaceuticals common stock. These options are compensation, not open-market purchases, and give him the right to buy shares at a fixed exercise price of $1.22 per share.
How many stock options did Andrew Saik receive from Milestone Pharmaceuticals (MIST)?
Andrew Saik received stock options for 77,000 shares of Milestone Pharmaceuticals common stock. The options are a derivative security, meaning they represent the right to purchase shares in the future under specified terms rather than current share ownership.
What is the exercise price and term of Andrew Saik’s Milestone (MIST) stock options?
The options have an exercise price of $1.22 per share and expire on June 10, 2036. This gives Saik a long-dated right to buy Milestone common stock at that price if the options vest and he chooses to exercise them.
How do the Milestone Pharmaceuticals (MIST) options granted to Andrew Saik vest?
The options vest in twelve equal monthly installments beginning July 10, 2026. They will be fully vested by the date of Milestone Pharmaceuticals’ next annual stockholder meeting, assuming Saik continues to provide service through each vesting date.
Is Andrew Saik’s Form 4 transaction for Milestone (MIST) a stock sale or purchase?
The Form 4 shows an acquisition of derivative securities as a grant or award, not an open-market stock sale or purchase. Saik received 77,000 stock options as compensation, classified as an “A” code transaction for a grant or award acquisition.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates